Media coverage about Catalyst Pharmaceuticals (NASDAQ:CPRX) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catalyst Pharmaceuticals earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.3931602342043 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Analysts Expect Catalyst Pharmaceuticals (CPRX) to Announce -$0.06 Earnings Per Share (americanbankingnews.com)
- Catalyst Pharmaceuticals Inc (CPRX) Insider Patrick J. Mcenany Acquires 20,000 Shares (americanbankingnews.com)
- 3 Things In Biotech, April 2: Catalyst Pharm Goes, Pfizer Flows, MediciNova Woes (seekingalpha.com)
- Catalyst Pharmaceuticals (CPRX) Raised to Hold at Zacks Investment Research (americanbankingnews.com)
- Catyalyst Pharma (CPRX) Announces Submission of NDA for Firdapse for Treatment of LEMS (streetinsider.com)
Several research firms have weighed in on CPRX. BidaskClub lowered Catalyst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, March 16th. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 15th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $6.25.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). sell-side analysts forecast that Catalyst Pharmaceuticals will post -0.36 EPS for the current year.
In related news, insider Patrick J. Mcenany acquired 20,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, April 3rd. The shares were acquired at an average cost of $2.29 per share, for a total transaction of $45,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.60% of the stock is owned by corporate insiders.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.